Key clinical point: Stereotactic ablative radiation therapy (SABR) may be able to extend progression-free survival among patients with oligometastatic prostate cancer, in part, by triggering a systemic immune response.
Major finding: At 6 months, 61% of patients in the observation group had experienced disease progression, compared with 19% of patients in the SABR group (P = .005).
Study details: A prospective, randomized, phase 2 trial involving 54 patients with oligometastatic prostate cancer.
Disclosures: The investigators disclosed relationships with RefleXion Medical, Pfizer, Genentech, and others.
Phillips R et al. ASTRO 2019. Abstract LBA3.